+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Thromboembolic complications of polycythemia: Polycythemia vera versus smokers' polycythemia



Thromboembolic complications of polycythemia: Polycythemia vera versus smokers' polycythemia



Journal of Vascular Surgery 17(3): 518-522



Purpose: This report compares patients with the hypercoagulable state of polycythemia vera to patients with secondary polycythemia caused by tobacco use to determine whether the incidence of thromboembolic events is equivalent. Methods: The medical records of 146 patients with the diagnosis of polycythemia between 1977 to 1990 were reviewed. Patients with transient, relative, or stress polycythemia were excluded from this study as were patients with polycythemia as a result of cardiac or pulmonary anomalies or both. The diagnosis of polycythemia vera (n = 43) was verified by use of the guidelines of the Polycythemia Vera Study Group. The diagnosis of polycythemia caused by smoking (n = 27) was based on an elevated total red blood cell volume, decreased oxygen saturation on arterial blood gas measurement, evidence of chronic obstructive pulmonary disease, and elevated carboxyhemoglobin levels. Results: Twenty-six patients (60%) with polycythemia vera and 11 patients (41%) with smoker's polycythemia had at least one thromboembolic problem. No significant differences existed between the groups with regard to age, hematocrit, or number of cardiac and cerebrovascular events. Overall, patients with polycythemia vera had a greater number of thromboembolic events per patient (p lt 0.05) and more peripheral arterial thromboemboli (p lt 0.005) than did patients with polycythemia as a result of smoking (Fisher's Exact Test). Conclusions: Thus the results of this study demonstrate that smokers' polycythemia does not represent a hypercoagulable state equivalent to that of polycythemia vera.

(PDF emailed within 0-6 h: $19.90)

Accession: 009646793

Download citation: RISBibTeXText

PMID: 8445747

DOI: 10.1016/0741-5214(93)90152-c


Related references

Polycythemia vera. V. Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells: a possible defect of phosphatase activity in polycythemia vera. Blood 89(10): 3574-3581, 1997

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials. Haematologica 102(6): E219-E221, 2017

Cerebro vascular complications of polycythemia vera a case report and incidence of polycythemia vera with apoplexy in japan. Clinical Neurology (Tokyo) 10(10): 585-592, 1970

Rapidly progressed aortic stenosis in a patient with previous diagnosis of polycythemia vera and post-polycythemia vera myelofibrosis. Clinical Case Reports 4(6): 589-592, 2016

Relation of polycythemia vera (Vaquez' disease) to myelosclerosis and leukosis. Polycythemia vera and so-called myeloproliferative states. La Revue du Praticien 12: 2399-2410, 1962

A clinical study of sixteen polycythemia vera cases--acute myeloblastic leukemia in patients with polycythemia vera. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(16): 2833-2837, 1994

The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 99(4): 1144-1149, 2002

Enhanced proliferation and phosphorylation due to vanadate are diminished in polycythemia vera erythroid progenitor cells A possible defect of phosphatase activity in polycythemia vera. Blood 88(10 SUPPL 1 PART 1-2): 145A, 1996

Comparison of erythroid progenitor cell growth in vitro in polycythemia vera and chronic myelogenous leukemia only polycythemia vera has endogenous colonies. Leukemia Research 13(4): 331-338, 1989

Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. American Journal of Hematology 16(4): 367-374, 1984

Acute leukemia , hydroxyurea and polycythemia vera An analysis of risk from the Polycythemia Vera Study Group. Blood 84(10 SUPPL 1): 518A, 1994

From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Seminars in Hematology 34(1): 17-23, 1997

Bayesian validation of Polycythemia Vera Study Group criteria for diagnosis of polycythemia rubra vera. Blood 86(10 SUPPL 1): 793A, 1995

The diagnosis and management of polycythemia vera in the Post-Polycythemia Vera Study Group era A survey of American Society of Hematology members practice patterns. Blood 94(10 SUPPL 1 PART 1): 114a, Nov 15, 1999

Uniform Decrease of the Initially Upregulated Polycythemia Rubra Vera-1 Gene mRNA Expression in Granulocytes of Polycythemia Vera Patients Treated with Interferon-Alpha. Blood 100(11): Abstract No 3154, November 16, 2002